Unleashing Innovation: The Role of Bispecific Antibodies in Managing Diffuse Large B-Cell Lymphoma
| Target Professions: | DO, MD, Nurse, Nurse Practitioner, Pharmacist, Physician Assistant |
| Target Specialties: | Hematology, Hematology/Oncology, Oncology |
| Credits Available: | 4.25 AMA PRA Category 1 Credit™/ MOC Points |
This dynamic course focuses on the exchange of best practices regarding the use of bispecifics in patients with R/R DLBCL including patient eligibility. Through this interactive, small-group activity, participants will review brief modules and patient cases to identify signs and symptoms of toxicities experienced while receiving treatment with bispecific antibodies for R/R DLBCL and also integrate protocols to manage CRS and ICANS effectively when managing patients. The group will gather for a live discussion via Zoom to share and exchange ideas on this topic.
CME/CE Accreditation Information
Itinerary
Part 1
The following questions will assess your baseline knowledge of DLBCL.
This module discusses clinical practice guideline third-line treatment recommendations for R/R DLBCL and the safety and efficacy data from clinical trials of epcoritamab and glofitamab, as well as patient eligibility considerations for these agents via a patient case discussion.
This module discusses the signs and symptoms of toxicities associated with bispecifics used in the treatment of R/R DLBCL and describes protocols for managing CRS and ICANS in this patient population.
Welcome to our module on improving collaboration between community providers and cancer centers to expand bispecific antibody use. Our faculty will discuss strategies to ensure access, focusing on practical approaches to overcome barriers and enhance outcomes.
Now that you have reviewed the self-study modules, answer the following questions to assess your gained knowledge of DLBCL.
We will dive into pivotal DLBCL-specific insights from each module, engaging in lively discussions on challenge submissions and sharing valuable feedback and comments.
Part 2
This activity features a 55-year-old woman with R/R DLBCL who is being treated with glofitamab.
This activity features a 63-year-old man with R/R DLBCL who presents to determine his best option for third-line treatment.
In light of the information reviewed and discussed during this program, please share an action plan that you will implement to improve the diagnosis and management for your patients with DLBCL.
We will discuss key points specific to DLBCL from each of the preceding modules, as well as answer any questions in an interactive discussion.
